|
1
|
Liou LS, Shi T, Duan ZH, et al: Microarray
gene expression profiling and analysis in renal cell carcinoma. BMC
Urol. 4:92004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
3
|
Chow WH, Devesa SS, Warren JL and Fraumeni
JF Jr: Rising incidence of renal cell cancer in the United States.
JAMA. 281:1628–1631. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amato RJ: Chemotherapy for renal cell
carcinoma. Semin Oncol. 27:177–186. 2000.PubMed/NCBI
|
|
5
|
Bukowski RM: Natural history and therapy
of metastatic renal cell carcinoma: the role of interleukin-2.
Cancer. 80:1198–1220. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Castellano G, Torrisi E, Ligresti G, et
al: The involvement of the transcription factor Yin Yang 1 in
cancer development and progression. Cell Cycle. 8:1367–1372. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zaravinos A and Spandidos DA: Yin yang 1
expression in human tumors. Cell Cycle. 9:512–522. 2010. View Article : Google Scholar
|
|
9
|
Riggs KJ, Saleque S, Wong KK, et al:
Yin-yang 1 activates the c-myc promoter. Mol Cell Biol.
13:7487–7495. 1993.PubMed/NCBI
|
|
10
|
Lee JS, Galvin KM, See RH, et al: Relief
of YY1 transcriptional repression by adenovirus E1A is mediated by
E1A-associated protein p300. Genes Dev. 9:1188–1198. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gronroos E, Terentiev AA, Punga T and
Ericsson J: YY1 inhibits the activation of the p53 tumor suppressor
in response to genotoxic stress. Proc Natl Acad Sci USA.
101:12165–12170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu S, Murai S, Kataoka K and Miyagishi M:
Cooperative regulation of p73 promoter by Yin Yang 1 and E2F1.
Nucleic Acids Symp Ser. 51:347–348. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brodersen P and Voinnet O: Revisiting the
principles of microRNA target recognition and mode of action. Nat
Rev Mol Cell Biol. 10:141–148. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim VN: MicroRNA biogenesis: coordinated
cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujita Y, Kojima K, Hamada N, et al:
Effects of miR-34a on cell growth and chemoresistance in prostate
cancer PC3 cells. Biochem Biophys Res Commun. 377:114–119. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Guessous F, Zhang Y, et al:
MicroRNA-34a inhibits glioblastoma growth by targeting multiple
oncogenes. Cancer Res. 69:7569–7576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei JS, Song YK, Durinck S, et al: The
MYCN oncogene is a direct target of miR-34a. Oncogene.
27:5204–5213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li N, Fu H, Tie Y, et al: miR-34a inhibits
migration and invasion by down-regulation of c-Met expression in
human hepatocellular carcinoma cells. Cancer Lett. 275:44–53. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tazawa H, Tsuchiya N, Izumiya M and
Nakagama H: Tumor-suppressive miR-34a induces senescence-like
growth arrest through modulation of the E2F pathway in human colon
cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang TC, Wentzel EA, Kent OA, et al:
Transactivation of miR-34a by p53 broadly influences gene
expression and promotes apoptosis. Mol Cell. 26:745–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu C, Kelnar K, Liu B, et al: The
microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang GL, Zhang XH, Guo GL, et al:
Clinical significance of miR-21 expression in breast cancer:
SYBR-Green I-based real-time RT-PCR study of invasive ductal
carcinoma. Oncol Rep. 21:673–679. 2009.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
26
|
Zhang S, Jiang T, Feng L, et al: Yin
Yang-1 suppresses differentiation of hepatocellular carcinoma cells
through the downregulation of CCAAT/enhancer-binding protein alpha.
J Mol Med. 90:1069–1077. 2012. View Article : Google Scholar
|
|
27
|
Pulikkan JA, Peramangalam PS, Dengler V,
et al: C/EBPalpha regulated microRNA-34a targets E2F3 during
granulopoiesis and is down-regulated in AML with CEBPA mutations.
Blood. 116:5638–5649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi Y, Seto E, Chang LS and Shenk T:
Transcriptional repression by YY1, a human GLI-Kruppel-related
protein, and relief of repression by adenovirus E1A protein. Cell.
67:377–388. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galvin KM and Shi Y: Multiple mechanisms
of transcriptional repression by YY1. Mol Cell Biol. 17:3723–3732.
1997.PubMed/NCBI
|
|
30
|
Tong ZT, Cai MY, Wang XG, et al: EZH2
supports nasopharyngeal carcinoma cell aggressiveness by forming a
co-repressor complex with HDAC1/HDAC2 and Snail to inhibit
E-cadherin. Oncogene. 31:583–594. 2012.PubMed/NCBI
|
|
31
|
de Nigris F, Crudele V, Giovane A, et al:
CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during
malignancy. Proc Natl Acad Sci USA. 107:14484–14489.
2010.PubMed/NCBI
|
|
32
|
Lee MH, Lahusen T, Wang RH, et al: Yin
Yang 1 positively regulates BRCA1 and inhibits mammary cancer
formation. Oncogene. 31:116–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Austen M, Cerni C, Luscher-Firzlaff JM and
Luscher B: YY1 can inhibit c-Myc function through a mechanism
requiring DNA binding of YY1 but neither its transactivation domain
nor direct interaction with c-Myc. Oncogene. 17:511–520. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang CC, Tsai MF, Dai TH, et al:
Synergistic activation of the tumor suppressor, HLJ1, by the
transcription factors YY1 and activator protein 1. Cancer Res.
67:4816–4826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Samarakoon R and Higgins PJ: Integration
of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen
activator inhibitor type-1 gene expression in vascular smooth
muscle cells. Thromb Haemost. 100:976–983. 2008.PubMed/NCBI
|
|
36
|
Girard N, Tremblay M, Humbert M, et al:
RARalpha-PLZF oncogene inhibits C/EBPalpha function in myeloid
cells. Proc Natl Acad Sci USA. 110:13522–13527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schuster MB and Porse BT: C/EBPalpha: a
tumour suppressor in multiple tissues? Biochim Biophys Acta.
1766:88–103. 2006.PubMed/NCBI
|
|
38
|
Lopez RG, Garcia-Silva S, Moore SJ, et al:
C/EBPalpha and beta couple interfollicular keratinocyte
proliferation arrest to commitment and terminal differentiation.
Nat Cell Biol. 11:1181–1190. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ramji DP and Foka P:
CCAAT/enhancer-binding proteins: structure, function and
regulation. Biochem J. 365:561–575. 2002.PubMed/NCBI
|
|
40
|
Pabst T and Mueller BU: Complexity of
CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer
Res. 15:5303–5307. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perrotti D, Cesi V, Trotta R, et al:
BCR-ABL suppresses C/EBPalpha expression through inhibitory action
of hnRNP E2. Nat Genet. 30:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sato A, Yamada N, Ogawa Y and Ikegami M:
CCAAT/enhancer-binding protein-alpha suppresses lung tumor
development in mice through the p38alpha MAP kinase pathway. PloS
One. 8:e570132013. View Article : Google Scholar : PubMed/NCBI
|
